Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions

Published:2022-11-10 Issue:3 Volume:43 Page:297-337
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Chen Yu‐Fei¹²,Xu Ying‐ying³,Shao Zhi‐Ming¹²,Yu Ke‐Da¹²^ORCID

Affiliation:

1. Department of Breast Surgery Fudan University Shanghai Cancer Center Shanghai 200032 P. R. China

2. Shanghai Medical College Fudan University Shanghai 200032 P. R. China

3. Department of Breast Surgery First Affiliated Hospital of China Medical University Shenyang Liaoning 110001 P. R. China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12387

Reference180 articles.

1. Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020

2. Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information

3. Breast cancer

4. The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer

5. LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer;Drug Resistance Updates;2024-11

2. Mechanism of Self-Assembled Celastrol-Erianin Nanomedicine for treatment of breast cancer;Chemical Engineering Journal;2024-09

3. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer;Journal of Experimental & Clinical Cancer Research;2024-08-21

4. Trop2-targeted therapy in breast cancer;Biomarker Research;2024-08-13

5. History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region;Frontiers in Pharmacology;2024-08-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3